Stock 301211 HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Equities

301211

CNE100005782

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 07/06/2024 am IST 		5-day change 1st Jan Change
15.2 CNY +1.67% Intraday chart for Hubei Biocause Heilen Pharmaceutical Co., Ltd. -7.32% -30.11%
17/05 Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation MT
28/04 Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 06 June 2024
CI
Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation
MT
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Dividend for the Year 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd.(XSEC:301211) added to S&P Global BMI Index
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payment Date Is 31 May 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301211 Stock
  4. News Hubei Biocause Heilen Pharmaceutical Co., Ltd.